Researcher
Xavier Saelens
- Keywords (Ghent University):antiviral immunity, virology, vaccines
- Disciplines (Flanders Institute for Biotechnology):Analytical biochemistry, Cell death and senescence, Analysis of next-generation sequence data, General diagnostics
- Disciplines (Ghent University):Applied immunology, Drug discovery and development not elsewhere classified, Clinical trials, Biopharmaceuticals, In vitro testing, Non-clinical studies, Animal immunology, Transcription and translation, Vaccines, Molecular and cell biology not elsewhere classified, Virology
Affiliations
- Department of Biochemistry and microbiology (Department)
Member
From1 Oct 2018 → Today - Saelens Lab
Responsible
From1 Jan 2017 → Today - Department of Biomedical molecular biology (Department)
Member
From1 Jan 1996 → 30 Sep 2018 - Department of Plant Biotechnology and Bioinformatics (Department)
Member
From1 Jan 1993 → 31 Dec 1995
Projects
1 - 10 of 44
- FullPicture: Combining Spectral Flow Cytometry with High-Speed Cell Imaging to enable comprehensive profiling of plant and animal cells and their components in real time.From1 May 2024 → TodayFunding: FWO Medium Size Research Infrastructure
- Virus ResearchFrom1 Jan 2024 → TodayFunding: BOF - projects
- Development of intrabody-expressing influenza virus vectors to discover new pro- and antiviral host factorsFrom1 Nov 2023 → TodayFunding: FWO Strategic Basic Research Grant
- New antivirals against human parainfluenza virusFrom1 Apr 2023 → 30 Sep 2024Funding: IOF - technology validation in lab
- Flow imaging microscope for advanced analysis of biopharmaceuticals and biological samplesFrom15 Dec 2022 → TodayFunding: BOF - scientific equipment program
- Prepared for SARS-CoV-3: advancing our understanding of SARS coronavirus antigenic and pathogenic evolutionFrom1 Jan 2022 → TodayFunding: FWO EOS
- A nanobody-based anti-inflammatory treatment against Pseudomonas aeruginosa-induced inflammation in chronic lung diseases.From1 Nov 2021 → TodayFunding: FWO Strategic Basic Research Grant
- A nanobody-based anti-inflammatory treatment against Pseudomonas aeruginosa-induced inflammation in chronic lung diseasesFrom1 Oct 2021 → 31 Oct 2021Funding: BOF - doctoral mandates
- A nanobody-based anti-inflammatory treatment against pathogen-induced chronic lung inflammationFrom1 Oct 2021 → TodayFunding: BOF - projects
- Designed, broadly protective antibodies directed against influenza B.From1 Nov 2020 → 31 Oct 2024Funding: FWO Strategic Basic Research Grant
Publications
1 - 10 of 168
- Systematic review and meta-analysis of genome-wide pooled CRISPR screens to identify host factors involved in influenza A virus infection(2024)
Authors: Annabel Maes, Alexander Botzki, Janick Mathys, Francis Impens, Xavier Saelens
- Promises and challenges of single-domain antibodies to control influenza(2024)
Authors: Arne Matthys, Xavier Saelens
- Repeated COVID-19 mRNA-based vaccination contributes to SARS-CoV-2 neutralizing antibody responses in the mucosa(2024)
Authors: Jozefien Declercq, Sarah Gerlo, Sharon Van Nevel, Natalie De Ruyck, Gabriële Holtappels, Els Tobback, Inés Lammens, Nikita Gerebtsov, Koen Sedeyn, Xavier Saelens, et al.
- Need for standardization of Influenza A virus-induced cell death in vivo to improve consistency of inter-laboratory research findings(2024)
Authors: Teodora-Eugenia Oltean, Jonathan Maelfait, Xavier Saelens, Peter Vandenabeele
- A new MVA ancestor-derived oncolytic vaccinia virus induces immunogenic tumor cell death and robust antitumor immune responses(2024)
Authors: Juan J. Rojas, Lien Van Hoecke, Miquel Conesa, Carmen Bueno-Merino, Ana del Canizo, Stephanie Riederer, Maria Barcia, Katrin Brosinski, Michael H. Lehmann, Asisa Volz, et al.
Pages: 2406 - 2422 - A neutralizing single-domain antibody that targets the trimer interface of the human metapneumovirus fusion protein(2024)
Authors: Marlies Ballegeer, Revina C. van Scherpenzeel, Teresa Delgado, Maria Iglesias-Caballero, Blanca García Barreno, Shubham Pandey, Scott A. Rush, Joost A. Kolkman, Vicente Mas, Jason S. McLellan, et al.
- Anti-neuraminidase and anti-hemagglutinin immune serum can confer inter-lineage cross protection against recent influenza B(2023)
Authors: João Portela Catani, Tine Ysenbaert, Anouk Smet, Marnik Vuylsteke, Thorsten U. Vogel, Xavier Saelens, Victor C. Huber
- GlycoVHH : optimal sites for introducing N-glycans on the camelid VHH antibody scaffold and use for macrophage delivery(2023)
Authors: Loes van Schie, Wander Van Breedam, Charlotte Roels, Bert Schepens, Martin Frank, Ahmadreza Mehdipour, Bram Laukens, Wim Nerinckx, Francis Santens, Simon Devos, et al.
- Cleavage of cFLIP restrains cell death during viral infection and tissue injury and favors tissue repair(2023)
Authors: Kristel Martinez Lagunas, Deniz Pinar Savcigil, Matea Zrilic, Carlos Carvajal Fraile, Andrew Craxton, Emily Self, Iratxe Uranga-Murillo, Diego de Miguel, Maykel Arias, Sebastian Willenborg, et al.
- Development of digital droplet PCR targeting the influenza H3N2 sseltamivir-resistant E119V mutation and its performance through the use of reverse genetics mutants(2023)
Authors: Laura Van Poelvoorde, François E. Dufrasne, Steven Van Gucht, Xavier Saelens, Nancy H. C. Roosens
Pages: 2521 - 2532
Patents
1 - 9 of 9
- CORONA VIRUS BINDERS (Inventor)
- METHODS OF GENERATING BROADLY PROTECTIVE VACCINE COMPOSITIONS COMPRISING NEURAMINIDASE (Inventor)
- MIXED-LINEAGE KINASE DOMAIN-LIKE PROTEIN IN IMMUNOTHERAPEUTIC CANCER CONTROL (Inventor)
- Anti-influenza antibody (Inventor)
- SINGLE DOMAIN ANTIBODY AGAINST RSV F PROTEIN (Inventor)
- METHODS OF GENERATING BROADLY PROTECTIVE VACCINE COMPOSITIONS COMPRISING NEURAMINIDASE (Inventor)
- MIXED-LINEAGE KINASE DOMAIN-LIKE PROTEIN IN IMMUNOTHERAPEUTIC CANCER CONTROL (Inventor)
- RESPIRATORY SYNCYTICAL VIRUS VACCINE (Inventor)
- Anti-influenza antibody (Inventor)